Sara Tolaney, MD, MPH (Chair) 
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute 
Associate Director
Susan F. Smith Center for Women’s Cancers 
Senior Physician
Dana-Farber Cancer Institute 
Associate Professor of Medicine
Harvard Medical School 
Boston, MA 

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner/Faculty:
Sara Tolaney, MD, MPH–reports the following financial relationships: Consultant to 4D pharma plc; Aadi Biosciences; Arch Therapeutics, Inc.; AstraZeneca; Athenex, Inc.; Bayer; BeyondSpring Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Certara, Inc.; Chugai Pharma USA, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Ellipses Pharma; Genentech, Inc./Roche; Gilead Sciences, Inc.; Infinity Therapeutics; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Mersana therapeutics; Myovant Sciences; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc.; OncoSec Medical Inc.; OncXerna Therapeutics, Inc.; Pfizer Inc.; Sanofi; Seattle Genetics; Inc.; Reveal Genomics; Umoja Biopharma; Zentalis Pharmaceuticals; Zetagen; and Zymeworks Inc. Research Support (paid to institution) from AstraZeneca; Bristol Myers Squibb Company; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Nektar; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi and Seattle Genetics, Inc. 

Faculty:
Information to come

Peer Reviewer:
Information to come

CEC Staff:
Katherine A. Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.